Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced that it has received financial support totaling $1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community, including CureDuchenne.
Halo will use the funds to expedite the phase 2 study of HT-100, its lead drug candidate for Duchenne muscular dystrophy (DMD). HT-100, a proprietary formulation of halofuginone, is an orally available small molecule drug candidate being developed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients. Halo will begin its phase 2 study in the second half of 2012.
“CureDuchenne is proud to be part of the Duchenne community that is financially supporting Halo,” said Debra Miller, CEO and founder of CureDuchenne. “It shows the power of the Duchenne community to help fast track therapeutics, such as treatment of fibrosis, to help our boys. We thank Charley’s Fund for initiating this research project.”
Click here to read the press release.